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Purpose or Objective: Radiotherapy (RT) is one of the most 
important curative options for treating localized prostate 
cancer (PC). At low α/β ratio of prostate tumors, HDR-
brachytherapy (HDR-BT) represents a way to perform an 
absolute and radiobiologic dose escalation. When using 3-D 
real-time planning systems it is possible to optimize 
treatment plans generating dose distributions with an 
integrated boost (SIB) to peripheral zone (PZ) without 
substantially increasing the dose to the organs at risk (OAR), 
especially the urethra. 
Aim: to analyze the dosimetric parameters (DP) and the 
acute toxicity of 30 consecutive patients (pts) treated with 
HDR-BT and a SIB to the PZ. 
 
Material and Methods: From January 2014 to September 
2015, 20 pts with intermediate/high risk PC were treated 
with combined external beam RT (EBRT 50 Gy/25 f) and HDR-
BT (2 x 9 Gy in the 2nd and 4th week of the EBRT). In the 
same period, 10 pts with low risk PC were treated with HDR-
BT monotherapy (3 x11.5 Gy, every 2nd week). In all implants 
a SIB of 20% (EBRT+HDR-BT) or 15% (HDR-BT monotherapy) to 
the PZ was planned. Equivalent dose at 2 Gy / fraction 
(EQD2), using α/β of 1.5 for target volumes and 3 for OAR, 
were calculated. 
 
Results: Median age was 68 years (range 56-76). DP are 
presented in table 1. In 33/40 implants in pts with 
EBRT+HDR-BT dose-escalation to the PZ was reached (range 6 
–44% of the prescribed dose). The median V100 for the 
prostate was 94.5% (CI ±1.6%). in 26/30 of the implants in pts 
with HDR-BT monotherapy the intended dose-escalation was 
reached (range 6 – 40% of the prescribed dose). The median 
V100 for the prostate was 92.8% (CI ±2.2%). No grade ≥3 
toxicity was observed. Grade 2 toxicity was 13% and resolved 
within 1 month in 90% of the pts. 
 
 
Conclusion: HDR-BT with SIB to the PZ is feasible in both 
combined and monotherapy settings. Acute toxicity was mild. 
Local control and late toxicity profile should be investigated 
prospectively. 
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Purpose or Objective: This prospective longitudinal study 
quantifies patient reported Quality of Life (QoL) pre-
treatment and up to ten years following permanent I-125 
prostate brachytherapy delivered as monotherapy in a single 
institution  
 
Material and Methods: 120 patients were asked to complete 
the Expanded Prostate Cancer Index Composite (EPIC) 
questionnaire, a comprehensive validated QoL tool designed 
to evaluate patient function and bother after prostate cancer 
treatment. Men completed the EPIC questionnaire before 
brachytherapy and at 8 time points after treatment (6 weeks; 
6,10 and 18 months; 2,3,5, and 10 years). At each time point 
clinically relevant small, moderate and severe declines in 
QoL were defined as 0.2-0.5 times SD, 0.5-0.8 times SD and > 
0.8 times SD of baseline function for each of urinary, bowel 
and sexual domains respectively. 
 
Results: Response rates in the first two years were >90% but 
thereafter dropped to 75% at 5 years and 48% at 10 years. 50 
patients (41.6%) responded at all stages. Maximal 
deterioration in mean urinary and sexual summary scores was 
noted 6 weeks after implant with severe urinary symptoms 
and moderate bowel/sexual symptoms at that point. At 6 
months urinary and bowel QoL had improved to mild 
impairment which then fully resolved by 10 months. Sexual 
QoL remained mildly impaired throughout the 10 years. At 10 
years new mild impairment of urinary and bowel QoL was also 
found. 
 
Conclusion: Clinically mild changes in urinary, bowel and 
sexual QoL are found 10 years after I-125 monotherapy. The 
impairment in sexual function persists from treatment but 
urinary and bowel symptoms are new at 10 years and may be 
either a late effect of brachytherapy or due to increasing 
age. 
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Purpose or Objective: Purpose: to evaluate the impact of 
the “image-guided” technology evolution on the implant 
quality in the interstitial brachytherapy with 125I seeds in 
the treatment of the prostate cancer. 
 
Material and Methods: Methods and materials: from April 
2004 until May 2014 we treated 306 patients with prostate 
cancer with permanent brachytherapy implants of radioactive 
125I seeds with a prescription dose of 145 Gy. The technology 
is changed during the years and we identify 4 groups relative 
to each different image-guided method. Group 1: 107 
implants from April 2004 until January 2007 using ultrasound 
guide in the transverse plane, fluoroscopic check and 
planning with 3D Prowess TPS; Group 2: 76 patients until 
October 2008 with Variseed 8.0 TPS and ultrasound both for 
transverse and longitudinal guide; Group 3: 43 patients until 
February 2010 with a “real-time” ultrasound guide both for 
transverse and longitudinal guide; Group 4: 80 patients with a 
new delivery system to assembly seed trains (Quicklink, 
BARD). For each group we calculate the mean D90 in the 
“postplanning” (evaluated on CT images after 60 days) and 
the difference between planning and postplanning in terms of 
D90 and V100 (dose fall-off). In the last group we evaluate 
also the difference, in terms of D90, V100 and maximum 
urethra dose between the theoretical planning and the 
effective implant, evaluated in the operating room on the 
ultrasound images at the end of the surgery. 
 
